why choose us

First received: August 08, 2022

Clinical Trial: Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Merkel Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Brief Summary: The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence.Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.

Read more